X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (50) 50
humans (49) 49
female (34) 34
male (33) 33
animals (31) 31
middle aged (28) 28
aged (26) 26
mice (26) 26
hematology (25) 25
oncology (25) 25
rituximab (25) 25
expression (19) 19
adult (18) 18
cyclophosphamide (17) 17
abridged index medicus (16) 16
aged, 80 and over (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
cell biology (16) 16
leukemia, lymphocytic, chronic, b-cell - drug therapy (16) 16
mice, knockout (16) 16
otorhinolaryngologic diseases (16) 16
macrophage migration-inhibitory factors - genetics (15) 15
prognosis (15) 15
survival (15) 15
cancer (14) 14
cytokines (14) 14
factor mif (14) 14
fludarabine (14) 14
macrophage migration-inhibitory factors - metabolism (14) 14
lymphoma (13) 13
macrophage migration-inhibitory factors - physiology (13) 13
macrophages (13) 13
research (13) 13
chemical and pharmacologic phenomena (12) 12
chemotherapy (12) 12
mice, inbred c57bl (12) 12
biochemistry & molecular biology (11) 11
chronic lymphocytic-leukemia (11) 11
lymphomas (11) 11
antibodies, monoclonal, humanized - administration & dosage (10) 10
antineoplastic agents - therapeutic use (10) 10
apoptosis (10) 10
immunology (10) 10
inflammation (10) 10
leukemia, lymphocytic, chronic, b-cell - mortality (10) 10
therapy (10) 10
animal diseases (9) 9
cells, cultured (9) 9
chronic lymphocytic leukemia (9) 9
macrophage migration inhibitory factor (9) 9
migration inhibitory factor (9) 9
respiratory system (9) 9
leukemia, lymphocytic, chronic, b-cell - pathology (8) 8
medicine, research & experimental (8) 8
open-label (8) 8
rituximab - administration & dosage (8) 8
treatment outcome (8) 8
analysis (7) 7
antibody (7) 7
article (7) 7
cyclophosphamide - administration & dosage (7) 7
cytokine (7) 7
disease-free survival (7) 7
follow-up studies (7) 7
ga101 (7) 7
health aspects (7) 7
macrophage migration-inhibitory factors - deficiency (7) 7
minimal residual disease (7) 7
prospective studies (7) 7
rheumatoid-arthritis (7) 7
rodents (7) 7
tumors (7) 7
antibodies, monoclonal, humanized - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
b-cell lymphoma (6) 6
biological factors (6) 6
care and treatment (6) 6
deficient mice (6) 6
follicular lymphoma (6) 6
gene expression (6) 6
in-vitro (6) 6
intramolecular oxidoreductases - genetics (6) 6
intramolecular oxidoreductases - metabolism (6) 6
leukemia, lymphocytic, chronic, b-cell - genetics (6) 6
mice, transgenic (6) 6
mif (6) 6
non-hodgkin-lymphoma (6) 6
obinutuzumab (6) 6
phosphorylation (6) 6
survival rate (6) 6
trial (6) 6
vidarabine - administration & dosage (6) 6
vidarabine - analogs & derivatives (6) 6
activated protein-kinase (5) 5
activation (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - adverse effects (5) 5
arthritis (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1164 - 1174
Summary Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal... 
Internal Medicine | CYTOKINE-RELEASE | MEDICINE, GENERAL & INTERNAL | PLUS CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | PROGRESSION-FREE SURVIVAL | INITIAL THERAPY | LYMPHOMA | STEM-CELL TRANSPLANTATION | EXPRESSION | III TRIAL | DELETION | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Incidence | Leukopenia - chemically induced | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Severity of Illness Index | Antibodies, Monoclonal, Murine-Derived | Drug Administration Schedule | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Rituximab | Treatment Outcome | Vidarabine - analogs & derivatives | Disease Progression | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Vidarabine - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Chronic lymphocytic leukemia | Cyclophosphamide | Fludarabine | Patient outcomes | Dosage and administration | Research | Drug therapy | Studies | Clinical trials | Mutation | Medical statistics | Epidemiology | Annual meetings | Teaching hospitals
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1081 - 1093
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2259 - 2266
PurposeTo perform an updated analysis of the randomized phase III GADOLIN trial in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated... 
MULTICENTER | PREDNISONE | THERAPY | ONCOLOGY | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | PHASE-III | VINCRISTINE | DOXORUBICIN | RISK
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 24, pp. 2646 - 2649
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1331 - 1344
Journal Article